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Abstract
Frozen sections (FS) of tumor samples represent a cornerstone of pathological intraoperative 
consultation and play an important role in the microscopic analysis of specimens during surgery. 
So far, immunohistochemical (IHC) stainings on FS have been demonstrated for a few markers 
using manual methods. Microfluidic technologies have proven to bring substantial improvement in 
many fields of diagnostics, though only a few microfluidic devices have been designed to improve 
the performance of IHC assays. In this work, we show optimization of a complete pan-cytokeratin 
chromogenic immunostaining protocol on FS using a microfluidic tissue processor, into a protocol 
taking less than 12 minutes. Our results showed specificity and low levels of background. The 
dimensions of the microfluidic prototype device are compatible with the space constraints of an 
intraoperative pathology laboratory. We therefore anticipate that the adoption of microfluidic 
technologies in the field of surgical pathology can significantly improve the way FSs influence 
surgical procedures.
Introduction
Frozen sections (FS) play an important role in the microscopic analysis of specimens during 
surgery. Surgeons may require an intraoperative consultation from pathologists for different 
purposes, ranging from the assessment of a resection margin in a tissue-conserving 
procedure, to the determination of a metastatic condition or the identification of the possible 
nature of lesions in exploratory surgeries1. In a large number of FS consultations, 
hematoxylin and eosin staining (H&E) is used by pathologists to seek whether the tumoral 
dissection presents a clear margin. Although the cost-benefit of the exhaustive use of FS is 
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under discussion for some procedures2,3, the clinical advantage is clear in most cases. Even 
for breast carcinomas, where cryosectioning is troublesome due to the high fat content4, 
studies showed that intraoperative assessment via gross examination and H&E of the 
margins can significantly decrease the re-operative rates5,6. Intraoperative methods based on 
H&E alone, even though very specific, often lack sensitivity7, which can be attributed to the 
absence of cancer cell-specific staining. Under these conditions, interpretation mostly relies 
on the experience of the pathologist, and a small number of infiltrating cancer cells into 
healthy tissue may not be easily recognizable. Studies show that false negative cases can 
reach values of 50% when the tumor size is smaller than 2 mm in breast cancer surgery, and 
that this rate can be significantly reduced using cytokeratin (CK) staining for intraoperative 
consultation of sentinel lymph nodes3. Numerous additional immunohistochemical markers 
would be interesting to test during intraoperative consultations, if only the turn-around time 
was not a limitation. Only for a few particular intraoperative consultations, 
immunohistochemistry (IHC) tests are available today. An example is the rapid IHC test for 
sentinel lymph nodes, which helps pathologists assess whether the lesions have metastized 
and surgeons determine what is the extent of the dissection.7–11 Another example is Mohs 
surgery of melanomas, where real-time margin analysis is required in order to ensure the 
lesion was fully dissected, while a maximum tissue preservation is guaranteed. IHC 
techniques using anti melanoma antigen recognized by T cell 1 (MART-1) antibodies have 
been proposed.12–14 A rapid (10 min) IHC test for the proliferation marker Ki-67 was also 
proposed as an adjunct to morphological diagnosis and grading of astrocytic tumors that can 
be performed intraoperatively.15 All these methods were based on the use of rapid IHC kits, 
specifically developed for a particular marker and tissue type, hindering more general use of 
the technique on other specimens and/or other markers of interest.
Technological improvements have significantly increased the throughput of IHC assays on 
formalin-fixed paraffin-embedded (FFPE) samples run by automated machines, both by 
reducing the staining time and parallelizing the number of assays. The first automats 
mimicked manual stainings by dropping reagents on top of horizontally disposed slides16. 
Nowadays, Ventana Medical Systems makes use of an inert liquid to avoid evaporation, and 
airstreams to increase reagent mixing16. The latest technology from Dako uses capillary 
forces to drive reagents by opening and closing the gap between the slide and a movable 
coverslip, and claims a turn-around time of 2.5 h for IHC16,17, showing the importance of 
boosting the reagent transport over the tissue section. Increased reagent transport has also 
been achieved in research settings by making use of an alternating electrical field on top of 
the tissue, leading to faster IHC staining 18,19. We have recently demonstrated that the use 
of microfluidics allowed to achieve fast immunostaining (<10 min) on FFPE sections with 
reagents that would normally require a minimum of 2 hours upon manual or automat-based 
process.20,21 So far, the capabilities of this technology have only been demonstrated for 
immunofluorescence staining of human epidermal growth factor receptor 2 (HER2) and CK.
In this work, we developed a complete pan-CK chromogenic staining protocol on FS using a 
microfluidic tissue processor (MTP) as the core technology of our stainer. Starting from an 
existing 43-min microfluidic protocol set up in our laboratory, we optimized each step to a 
working protocol in less than 20 min, including tissue preparation after cryosectioning in 7 
minutes and immunohistochemichal staining in less than 12 minutes. This optimized 
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protocol was tested on different frozen tissue types. Since the increased time performance 
relies on the microfluidic handling and not on the reagents themselves, our technique has the 
potential to provide pathologists with a versatile tool for fast IHC stainings on frozen 
sections of any type. Moreover, the microfluidic characteristics allowed us to develop an 
experimental prototype that matches the space constraints often found in FS laboratories. We 
believe that many more questions could be answered intraoperatively with the use of our 
new technology to reduce the turn-around time of IHC assays.
Material and Methods
Sample preparation
Anonymized frozen samples were obtained from the Institute of Pathology at the Centre 
Hospitalier Universitaire Vaudois (CHUV). Ethical approval was obtained from the 
“Commission cantonale d'éthique de la recherche sur l'être humain” (CER-VD) under the 
protocol number 511/12. The samples included ureter, pancreas, prostate, breast carcinoma, 
pancreas adenocarcinoma, lung adenocarcinoma (NSCLC) and Hodgkin lymphoma. The 
details of the protocol steps are shown in Table 1. Frozen tissue blocks were cut with a 
cryostat (Leica, CM1850) with a thickness of 4 and 10 microns, and mounted on standard 
histopathology slides (step 1) at the Histology Core Facility (HCF) of the Ecole 
Polytechnique Fédérale de Lausanne (EPFL). In the optimized MTP protocol (Table 1iii), 
sections were dried (step 2) using cold air of an air-flow dryer for 2 min, fixed (step 3) for 3 
min in cold acetone (kept at -20°C prior to the experiment, Fischer Chemicals, A/0600/15) 
and dried again (step 4) with the air-flow dryer using cold air for 2 min. All the subsequent 
steps of the staining were performed on the MTP-device (referred to as “On chip” in Table 
1). Several reagents were tested during optimization of the pre-staining steps: fixation with 
methanol during 10 min (-20°C, Fischer Chemicals, M/4000/15) immediately after 
sectioning; fixation with acetone for 10 min (on ice, Fischer Chemicals, A/0600/15) 
immediately after sectioning; and tissue dehydration at temperature for 15 min or using air 
flow for 2 min.
Microfluidic setup
Once the frozen sample preparation is completed, the tissue section is clamped using a 
gasket to the MTP to form a reaction chamber of 17x17 mm2, after which the system is 
ready for fast IHC staining (Figure 1a). Reagents are delivered through microfluidic 
channels in the chip to the reaction chamber, where the staining takes place (Figure 1b). The 
MTP enables a fast fluidic exchange on a one-second timescale. Additional details about the 
MTP working principle can be found elsewhere20. Figure 1c shows a schematic of the 
automated pressure-driven laboratory setup that was used for the experiments. The setup 
consisted of: (i) 50 mL reservoirs used for common reagents, namely phosphate-buffered 
saline (PBS), deionized water (DIW), 3,3'-diaminobenzidine (DAB), and ethanol; (ii) 1.5 
mL Eppendorf tubes for specific reagents, such as antibodies, blocking solutions and 
hematoxylin; (iii) a computer-operated valve-manifold called Reagent Delivery System 
(RDS) used to select among the reagents to be flushed into the reaction chamber; (iv) the 
MTP/tissue sample staining chamber. Figure 1d shows a picture of the prototype used for the 
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experiment. The inset (i) shows the manual mechanism for insertion of the MTP in the 
machine.
MTP-based stainings
After the tissue was dried and clamped to the MTP, the “On chip” steps in columns (ii) and 
(iii) from Table 1 were performed. The protocol was defined on a graphical user interface 
and executed entirely by the automated laboratory setup. Tissue rehydration (step 5) and all 
the washing steps were realized using Tris Buffered Saline solution (TBS, Sigma Life 
Science, T5912-1L). Blocking solutions (step 6 and 7) were not used in the optimized MTP 
protocol. Primary antibody (Ab) incubation (step 8) was done using mouse anti-human CK 
(Dako, M3515), diluted 1/100 in TBS Tween 0.05% (Tween 20, Fischer Scientific, 
BP337-100). The step of incubation with post-primary Ab (step 9) used in column (ii) was 
not performed in the optimized protocol of column (iii). After primary Ab application, tissue 
sections were directly incubated with ImmPRESS (Vector Laboratories, MP-7402), a micro-
polymer conjugated with anti-mouse secondary Ab and horseradish peroxidase (HRP) 
enzyme molecules (step 10). The reaction was revealed (step 11) using the 3,3'-
diaminobenzidine (DAB) chromogen (ImmPACT, Vector SK-4105) and the nuclei 
counterstaining (step 12) was achieved using hematoxylin Gill3 20% (Thermo Scientific, 
72604). Finally, slides were washed, unclamped from the MTP and coverslipped (mounting 
solution from Sigma, F6182-20). All negative controls (CTL) were obtained by performing a 
parallel staining by replacing the primary Ab by a solution of TBS Tween 0.05%.
During optimization, alternative detection kits were tested: ImmPRESS Excel (Vector, 
MP-7602), Novolink (Novocastra, Biosystems, RE7290), and Quanto (Thermo Scientific, 
TL-060-QHD). Each of these kits provided its own peroxidase block (step 6), protein block 
(step 7), amplifier or post-primary Ab (step 9), polymer (step 10) and DAB buffer (step 11). 
Additional DAB chromogens were tested: DAB EqV (Vector, MP-7602), DAB Reveal 
(Spring, DABC-001/15), DAB Novolink (Novocastra, Biosystems, RE7105/06), DAB Metal 
enhanced (Thermo Scientific 34065/1855910). Counterstaining tests were also done with 
hematoxylin from Novolink (Novocastra, Biosystems, RE7107) and hematoxylin QS (Vector 
H-34004).
H&E stainings
The total time needed for the optimized H&E protocol execution was 2:30 min. Slides were 
stained with hematoxylin QS (Vector, H-34004) and then rinsed with tap water. A second 
rinsing was then applied using ethanol 100% (Fischer Chemical, E/0650DF/15). 
Subsequently, tissue sections were stained using eosin Y 1% (Sigma, E4382) in 70% ethanol 
with 1% phloxine (Fluka, 28550) for 15 s, rinsed again with ethanol 100% and then tap 
water. Finally, specimens were unclamped from the MTP and coverslipped using DPX 
mounting media for histology (Sigma, 06522-100ML).
Imaging
Images of stained slides were taken using a slide scanner (VS-ASW FL, Olympus) with a 
20x 0.75 NA objective. A color depth of 24-bit and a resolution of 346 nm/pixel was 
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achieved and saved in .vsi format. The extracted images were exported as TIFF images using 
Fiji Image J and a plugin provided by the Bioimaging and Optics Platform (BIOP) of EPFL.
Manual controls
Manual staining controls were performed using the exact same dilutions and incubation 
times as in the optimized MTP-based stainings and are detailed in column (iii) of Table 1. 
Due to the need of manually handling the tissue, an additional 5 minutes per slide were 
required to remove the excess of liquid in between incubation steps.
Results
Pre-staining protocol optimization
The common tissue preparation steps, referred to as “pre-staining” in Table 1, were 
optimized on ureter autopsy specimens, from an initial total time of 55 min to a final time of 
8 min. The five pre-staining steps were (1) sectioning, (2) first drying, (3) fixation, (4) 
second drying, and (5) re-hydration. Step 1 was not optimized, as being part of a service 
from HCF. Steps 2 to 4 were optimized off-chip, while step 5 was first performed off-chip 
(column (ii) of Table 1), then included on-chip (column (iii) of Table 1),. Figure 2a shows a 
comparison of CK staining obtained using fixation by methanol (at 4°C) and acetone (kept at 
–20°C prior to the experiment). In direct acetone fixation, the tissue is immersed in acetone 
immediately after sectioning, while for the indirect mode, the tissue is sectioned, dried for 
15 min at room temperature, and then immersed in acetone. Indirect fixation with acetone 
showed the best staining. In Figure 2b, the optimization of the acetone indirect fixation time 
is shown, where fixation times between 10 min to 1 min were tested. Three-minute fixation 
turned out to be sufficient to obtain a clear staining. Increasing the fixation time above three 
minutes resulted in no apparent improvement, while shorter fixation times increased the 
areas where the staining was not present or was fainter. Figure 2c depicts the results of the 
optimization of the second drying time (step 4 in Table 1), showing satisfactory results using 
cold air of an air-flow dryer for 2 min, instead of passive drying over 15 min. The same 
drying procedure was applied for first drying in step 2. Figure 2d shows how the rehydration 
step, prior to staining, could be successfully achieved in 1 min, once the slide was clamped 
to the MTP.
MTP staining protocol staining protocol optimization
Once the optimum times for the pre-staining steps were found, the choice of ImmPRESS as 
our detection system was done based on a direct comparison test that can be found in the 
Supplementary Information (Figure S1). Subsequently, the steps corresponding to “staining 
part I” of Table 1 were optimized. Figure 3a shows that the use of a blocking buffer, 
standardly done in the manual protocol, did not improve the quality of the staining in 
microfluidic IHC, which was the reason why it was removed from from the optimized 
protocol in column (iii) of Table 1. Figure 3b and 3c show the optimization of the primary 
Ab and the secondary Ab incubation times, respectively. Incubation during 2 min for the 
primary Ab and 4 min for the secondary Ab were sufficient to obtain a high-quality staining. 
Such short Ab incubation times using the MTP technology had already been demonstrated 
before for immunohistofluorescence assays in in our laboratory20,21.
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“Staining part II” steps from Table 1 were optimized by both the choice of the reagents that 
gave the best imaging result and the shortest incubation times. Figure 4a shows the 
incubation time optimization of the DAB obtained from the kit Novolink, which was used as 
our reference standard during the experiments described above. Increasing the DAB 
incubation time between 30 s and 90 s showed an increment in the intensity of staining. 
However, no difference was perceived between 90 s and 150 s, indicating that incubation 
longer than 90 s was not necessary. Subsequently, DAB reagents from five different 
providers were compared under the same experimental conditions and shown in Figure 4b. 
ImmPACT was selected as giving the best staining results in the IHC MTP settings. 
Similarly, in Figure 4c, three hematoxylin suppliers were compared, giving Gill3 as the most 
suitable choice of hematoxylin for our experiments. The incubation time of Gill 3 
hematoxylin was optimized down to 15 s (Figure 4d). Finally, the hematoxylin solution was 
diluted to 20% of its original concentration using DIW, resulting in lesser viscosity without 
compromising staining (Figure 4e).
Optimized MTP H&E and CK staining results for different tissue types
Figure 5 shows images of the H&E (first column), CTL (negative control, second column) 
and CK (third column) stains using the MTP optimized protocols, performed on the 
following samples: pancreas, ureter, prostate, breast carcinoma, pancreas adenocarcinoma, 
lung carcinoma (NSCLC) and Hodgkin lymphoma. Successful H&E stains were achieved 
for all the tissue types used in our study and the turn-around time was 2 minutes and 30 
seconds. CK staining showed specificity to epithelial cells on non-cancerous tissues and on 
carcinomas of different origin. At the same time, no false-positive staining was observed on 
lymphoma cases. Similarly, the negative controls, where the protocols were run without 
primary anti-CK Abs, showed only nuclear counterstaining, as expected.
Manual controls
Manual staining experiments were performed on all the tissues shown in Figure 5 using the 
incubation times of the on-chip experiments, as detailed in Table 1 (iii). The images of these 
stainings are shown in Figure S2 of the supplementary information. Results showed that in 
most cases the background is significantly higher when compared to on-chip experiments.
Discussion
Microfluidics has already proven to bring substantial improvement in many fields of 
diagnostics, with point-of-care applications being the most popular22. Seemingly, 
laboratory-based microfluidics enabled improvements in genomics, sequencing, high-
throughput screening, and separations. The higher surface-to-volume ratio achieved by 
handling reagents in the micrometer scale allows for higher sensitivity and assay turn-
around-time. Surprisingly enough, only a few microfluidic devices have been designed to 
improve the performance of IHC assays used in the field of tissue diagnostics23,24. While 
these devices confine the staining on a small portion of the tissue section, the MTP is 
designed to deliver and wash reagents over the entire tissue surface in down to one second.
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We demonstrated that our microfluidic technology can deliver fast (<12 min) and automated 
IHC stains using conventional anti-CK Abs on multiple frozen tissue types.. Results showed 
specificity to cells of epithelial origin and low levels of background in the negative controls. 
The dimensions of the prototype used for the experiments is compatible with the space 
constraints typically observed in intraoperative laboratories. The need for fast pathological 
examination during surgery makes FSs one of the most challenging tasks that the pathologist 
performs in practice. As of today, except for a few dedicated fast IHC kits7–15,18,25, 
intraoperative diagnosis is based on H&E alone and confronted post-operatively to the 
corresponding permanent sections. Rapid and automated IHC tests made available at the 
intraoperative laboratory would significantly add to the accuracy of the diagnosis for the 
most complicated cases. The method developed in this study is limited to only one marker. 
Reproducibility was addressed using the same protocol for 7 different tissue types, which is 
not sufficient for a full validation of the protocol. Cases were selected retrospectively and 
frozen samples were cut on demand, thus neither represents a validation for a clinical use 
nor for any specific use of the marker. A prospective study is required to attribute clinical 
value. Finally, even though this method performed well on tissue sections where the marker 
of interest is highly expressed, there is no evidence that it will reach the level of sensitivity 
required for some assays. Analytical sensitivity and specificity was not addressed 
quantitatively in this study. It is clear that more is to be done in order to offer pathologists a 
tool for IHC diagnosis on FSs, in particular the availability of a broader panel of markers. 
We anticipate that the adoption of microfluidic technologies in the field of surgical 
pathology can then significantly improve the way FS analysis influence surgical procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Working principle of microfluidic staining of FS.
(a) Once the frozen sample preparation is completed, the sample is clamped using a gasket 
to the Microfluidic Tissue Processor (MTP) to form a reaction chamber of 17x17 mm2, after 
which the system is ready for fast IHC staining. Microfluidic channels deliver reagents to 
and from the reaction chamber. Staining takes place only in the chamber (b) Schematic 
cross-section of the MTP clamped to the tissue slide. Inside the reaction chamber, reagents 
are sequentially delivered and washed over the surface of the tissue section. The MTP 
enables a fast fluidic exchange on a one-second timescale, while keeping reagent exposure 
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times uniform throughout the whole tissue surface. (c) Schematics of the laboratory setup 
used for the experiments: (i) 50 mL reservoirs are used for common reagents, namely PBS, 
DIW, DAB, and hematoxylin; (ii) 1.5 mL Eppendorf tubes are used to load specific reagents, 
such as antibodies, and blocking solutions; (iii) a computer-operated valve-manifold called 
Reagent Delivery System (RDS) allows for the selection of the reagents that are flushed into 
the chamber of reaction; (iv) MTP/ tissue sample staining chamber. (d) Picture of the 
prototype used for the experiments. The inset (i) shows the mechanism of manual insertion 
of the MTP in the machine.
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Fig. 2. Optimization of the pre-staining protocol on ureteral biopsy sections.
Slides show the final CK staining and are compared with negative control (CTL) samples, 
obtained by staining without use of the primary Ab, in which case, ideally, only nuclear 
hematoxylin counterstaining is visible. The immunohistochemical staining of frozen 
sections described in this work requires a set of common tissue preparation steps (see Table 
1): (1) sectioning, (2) first drying, (3) fixation, (4) second drying, and (5) re-hydration. Step 
1 was neither optimized nor counted within the total time of the IHC assay. Steps 2 to 4 were 
optimized off-chip. (a) Comparison of CK staining obtained using fixation by methanol (at 
4°C) and acetone (kept at –20°C prior to the experiment). In direct acetone fixation, the 
tissue is immersed in the acetone immediately after sectioning. Indirect means that the tissue 
is sectioned, dried for 15 min at room temperature, and then immersed in the acetone. 
Indirect fixation with acetone showed best staining. (b) Optimization of the acetone indirect 
fixation time. Three-minute fixation turned out to be sufficient to obtain a clear staining. 
Increasing the fixation time resulted in no apparent improvement, while shorter fixation 
times increased the areas where the staining was not present or was fainter. (c) Optimization 
of the second drying time (step 4 in Table 1) showed satisfactory results using an air-flow 
dryer for 2 min. (d) One-minute successful re-hydration was achieved by clamping the 
section to the MTP. The blue frames on each panel represent the ‘best conditions’ chosen for 
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the final experiments of Figure 5 and are represented in column (iii) of Table 1 (Scale bars: 
50 μm; bottom-left code: identifier of the sample in Table S1).
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Fig. 3. Optimization of the first part of the MTP staining protocol of Table 1 on ureteral biopsy 
sections.
Slides show the final CK staining and are compared with CTL samples, obtained by staining 
without use of the primary Ab. (a) Use of a blocking buffer, standardly done in the manual 
protocol, did not improve staining in microfluidic IHC, which was the reason to remove the 
blocking step from the optimized protocol in column (iii) of Table 1. (b) Optimization of the 
primary Ab incubation time. Incubation during 2 min was sufficient to obtain a high-quality 
staining. (c) Optimization of the secondary Ab incubation time. 4 min was chosen in the 
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initial MTP protocol of column (ii) of Table 1. The blue frames on each panel represent the 
‘best conditions’ chosen for the final experiments of Figure 5 and are represented in column 
(iii) of Table 1. (Scale bars: 50 μm; bottom-left code: identifier of the sample in Table S1).
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Fig. 4. Optimization of the second part of the MTP staining protocol of Table 1 on ureteral 
biopsy sections.
(a) Optimization of the incubation time of DAB obtained from the Novolink kit. Increasing 
the DAB incubation time between 30 s and 90 s increases the intensity of the signal. 
However, no difference is perceived between 90 s and 150 s, indicating that incubation 
longer than 90 s is not necessary. (b) DAB reagents from 5 manufacturers were compared 
under the same experimental conditions. ImmPACT was selected as giving the best staining 
quality. (c) Three hematoxylin suppliers were compared, giving as most suitable choice 
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hematoxylin obtained from Gill3. (d) The optimized hematoxylin incubation time was 
chosen as 15 s. (e) Finally, we diluted the hematoxylin solution to 20% of its original 
concentration using DIW, resulting in lesser viscosity and eosin application without 
compromising the staining. (Scale bars: 50 μm; bottom-left code: identifier of the sample in 
Table S1).
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Fig. 5. Results of the optimized MTP staining protocol for different tissue types for CK in IHC 
(less than 12 minutes) and H&E (2:30 minutes).
Optimized H&E staining (first column), CTL staining (negative control, second column), 
and CK staining at 3 magnifications: scale bar 200 μm (third column), scale bar 50 μm 
(fourth column) and 20 μm (fifth column) performed on the following samples: pancreas (a), 
ureter (b), prostate (c), breast carcinoma (d), pancreas adenocarcinoma (e), lung carcinoma 
(NSCLC) (f), Hodgkin lymphoma (g). The H&E stainings were performed on the MTP in 
2:30 minutes. CK staining showed specificity to epithelial cells on non-cancerous tissues 
and on carcinomas of different origin. At the same time, no false-positive staining was 
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observed on the lymphoma case. Similarly, the negative controls, where the protocols were 
run without primary anti-CK Abs, showed only nuclear counterstaining, as expected. (Scale 
bars: 50 μm for columns 1, 2 and 4; 200 μm for column 3 and 20 μm for column 5).
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Table 1
Staining protocols.
Details of the complete protocol for (i) manual staining, (ii) initial MTP protocol, which was based on 
previous experiments on formalin-fixed paraffin-embedded samples20,21 and (iii) optimized MTP protocol 
realized in this study. Washing steps, performed in-between the described steps, are not explicitly mentioned. 
The overall washing time is shown at the end of the table.
Step number Group Step (i)
Manual protocol
Time (min)
(ii)
Initial MTP protocol
Time (min)
(iii
Optimized MTP protocol
Time (min)
1 PRE – STAINING Sectioning 0.0 Off chip 0.0 Off chip 0.0 Off chip
2 First drying 15.0 15.0 2.0
3 Fixation 10.0 10.0 3.0
4 Second drying 15.0 15.0 2.0
5 Re-hydration 15.0 15.0 1.0 On chip
PRE-STAINING subtotal 55.0 55.0 8.0
6 STAINING PART I Peroxidase block 5.0 2.0 On chip 0.0
7 Protein block 5.0 2.0 0.0
8 Primary antibody 30.0 4.0 2.0
9 Post primary 30.0 4.0 0.0
10 Secondary antibody 30.0 4.0 4.0
11 STAINING PART II DAB 5.0 2.5 Off chip 1.5
12 Counterstaining 5.0 4.0 0.3
STAINING subtotal (no washing) 110.0 22.5 7.8
Washing 105.0 5.8 3.3
STAINING subtotal 215.0 28.3 11.1
TOTAL 270.0 83.3 19.1
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